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In this manuscript, we report the current situation of tuberculosis globally and in Brazil,
the  need for new strategies toward tuberculosis control, focusing on new diagnostic tech-
nologies.  Critical comments are given on the state of the art regarding the evaluation of
new health technologies, degree of scientiﬁc evidence needed, evaluation of clinical impact,
cost-effectiveness  of incorporation into the health system and the social impact.
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uberculosis (TB) is a major public health problem in the world,
ith  incidence differing by regions. It is estimated that in 2010,
pproximately 8.8–9.2 million new TB cases arose, of which 4
illion did not receive treatment. Treatment outcomes have
een  poor in countries that have not adopted the DOTS strat-
gy  proposed by the World Health Organization (WHO) in 1993,
nd  where effective TB control actions were implemented,
ave been hampered by lack of political commitment and/or
isorganization of the health system, associated to poverty,
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Este é um artigo Open Access sob a licençasocial exclusion, and the burden of human immunodeﬁciency
virus (HIV) or multidrug-resistant (MDR) or extensively drug-
resistant  (XDR) TB.1
As one of the emerging middle-income countries, Brazil
ranks  19th among the 22 countries which account for 80%
of  all TB cases worldwide and 108th in incidence.2,3 Accord-
ing  to the Ministry of Health, in 2010, 71,000 cases of TB were
reported  in the National Reporting Case System (SINAN), for
which  the cure rate was  66.4% and the defaulting rate was  11%dade de Medicina, Departamento de Clínica Médica, Rua Professor
se, Ilha do Fundão, Rio de Janeiro, RJ 21941-913, Brazil.
(which  ideally should be below 5%). The percentage of cases on
Directly Observed Therapy (DOT) was  only 38%. It is estimated
that  among TB patients co-infected with HIV, the cure rate was
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55.7% and death rate was  23% (5.7 times greater than for HIV-
seronegative patients). In 2008, among the twelve measures
for  collaborative TB-HIV control proposed by WHO,  only three
were  adopted by both programs  of the Ministry of Health in
Brazil.
In  2006, WHO’s Global Plan to Stop TB4 expanded the DOTS
strategy  (renaming it the Stop TB Strategy). This plan priori-
tized  the strengthening of the health system; the pursuit of
public–public  and public–private partnerships; social mobi-
lization  and the reevaluation of the academic role (forgotten
since  the 1970s for its contribution to TB control efforts), in
order  to seek new ways to increase the effectiveness of DOTS,
improve  access to services, and increase the diagnosis and
cure  rate of TB, including those with MDR-TB and co-infected
with  HIV.5
Despite the fact that acid fast bacilli (AFB) sputum smear
microscopy has a low sensitivity (60%), it remains one of the
most  frequently used tests for the diagnosis of pulmonary
TB  in low-income countries.1 In addition, in HIV-infected
patients, children or patients with other immunosuppress-
ive diseases, the sensitivity of smear microscopy is much
lower  (<30%).6 In most high burden countries, in practice,
the  mycobacteria culture, for which diagnostic sensitivity is
higher (80–85%) it is performed on solid Lowenstein–Jensen
(LJ) medium but is used only in selected clinical cases (cases
of  treatment failure, patients with persistent smear-negative
or  extra-pulmonary forms). The major problem in the use of
LJ  for diagnosing tuberculosis is the long incubation time (4–6
weeks),  and since the drug sensitivity testing (DST) is per-
formed  from the culture and not from the clinical specimen,
several additional weeks are required to obtain the results.7
In HIV-positive patients and in children, the strategy pro-
posed  by WHO  to prioritize the assessment of respiratory
symptoms (cough for more  than 2–3 weeks) to search for pul-
monary  TB has been inadequate. Recently, Cain et al.8 and
Marais  et al.9 proposed an innovative approach regarding the
evaluation  of clinical scores and radiological diagnosis of pul-
monary  TB in different epidemiological settings, for adults
and  children. They highlighted the urgent need for evaluation
of  new diagnostic approaches that promote greater impact
on  the region(s) most affected by coinfection TB-HIV and/or
MDR-TB.10 Additionally, due to the absence of laboratories
capable of routinely performing culture and DST, there are
few  reliable data on MDR- or XDR-TB among the 22 high bur-
den  TB countries. In 2010, it has been estimated that there
were  650,000 cases of MDR-TB, with cure rates less than 60%,
higher  rates of morbidity/mortality and increased treatment
costs.  Of these MDR-TB cases, only 8.5% were diagnosed and
an  even smaller proportion of them had access to appropri-
ate  treatment.11 Therefore, the evaluation of new diagnostic
technologies is needed urgently, but different detection strate-
gies  that also include an analysis of factors associated with
access,  linked to the patient and/or health system must be
considered.12
In Brazil, in 2010, cultures for mycobacteria were performed
in  only 30% of retreatment cases, even though national policy
is  to have them done for all such cases.13 In addition, only
22%  of TB cases with a positive serology for HIV and 36% of all
prisoners  had a culture done, even though the same national
policy  applies. These data demonstrate the difﬁculty in Brazil 1 3;1 7(2):211–217
of  providing adequate coverage for the diagnosis of TB. Due
to  the low coverage for culture (DST was  performed only in
30.7%  of the cases that are supposed to have it according to
Brazilian  policy), the number of MDR-TB cases in the country
is  probably deeply underestimated. In these patients, the cure
rate  does not exceed 65%, those who default from treatment
is  greater than 20% and the proportion of those who  die is over
12%.  Therefore in Brazil, in order to increase access, equity, the
quality  of TB diagnosis, reduce defaulting from treatment and
provide  more  social services or health care of their families,
it  is urgent to prioritize collaborative activities between the
TB  and AIDS control programs, and also with primary health
care  (PHC) programs  at the three government levels: federal,
state  and municipal, along with the support of the academic
community and civil society. Such activities will enable the
development and evaluation of the impact of the adoption of
new  strategies for TB, TB-HIV, and MDR-TB.
Evaluation  of  new  technologies  and  strategies
in the  control  of  TB,  TB-HIV,  MDR-TB
Enabling and promoting research are key components of the
Stop  TB Strategy, and should be pursued vigorously. Clearly,
new  and better technologies for the prevention, diagnosis,
treatment and care of active and latent TB and its associ-
ated  conditions and complications are needed. However, this
will  not be sufﬁce. Innovative approaches also must con-
tinue  to be developed to ensure equitable access to these
technologies.14 In addition, those approaches involving oper-
ational  and cost-effectiveness evaluation should be adapted
and  adjusted based on the epidemiological context of the local
health  system.
Most  of the innovations cannot be translated into effective
action  without careful local planning and adaptation. Oper-
ational  research needs to be conducted in a well-planned
manner that is distinct from the routine monitoring carried
out  to assess the epidemiological situation of the national
and  local health system. Only then can proper arrangements
of  different applications for local interventions be identiﬁed.
However, there are many  hurdles to this essential step in the
chain  of events from basic research to practical application.
National TB, AIDS and PHC programs  generally have limited
capacity  to conduct operational research and often do not
have  a development agenda for it. So there is a need for guid-
ance  on what issues to investigate, how to do it and how
to  strengthen the capacity for operational research.There are
several  ways and steps to assess the potential value of a diag-
nostic  test/strategy for clinical use, but the choice of the model
depends  on proper determination of the question that needs
to  be answered.
The  current  focus  on  accuracy
The ﬁrst question that arises for a new test/strategy is whetherresults  found in healthy individuals. To answer this question,
the  study should be conducted in individuals with known dis-
ease  and in those who are healthy, checking the results in
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ach of these groups. This study begins with the evaluation
f  the sensitivity, speciﬁcity and accuracy of a new diagnostic
est  for a given disease. This type of study does not imply a
iagnostic  action, but it is an early stage of the process, usu-
lly  with greater involvement of researchers in the basic and
pplied  basic research arena, linked to research laboratories
n  universities, research institutes and industry.14 The next
tep  is to question whether the new test/strategy is able to
istinguish  individuals with active TB and those TB suspects
with  no TB) seeking medical care. In this evaluation phase
n  more  traditional clinical research centers, this is based on
omparison  of the new test/strategy with a reference test or
old  standard, to derive measures of diagnostic accuracy, such
s  sensitivity and speciﬁcity. These studies provide scientiﬁc
vidence  and consist almost entirely of reviews of new diag-
ostic  tests/strategies for TB in the published literature and
sed  as evidence in recent years. These studies have been
onducted in the clinical research centers, in universities, and
esearch  institutes usually linked to industry support.
he  GRADE  system,  systematic  reviews  and
heir limitations
aking adequate decisions on health, including on the diag-
ostic  method to be used, means not only putting on a scale
he  available evidence about the risks and beneﬁts of alterna-
ive  strategies, but also depends on the conﬁdence that their
ndings  can inspire. This recognition led to the emergence of
 series of formal systems to categorize the quality of scientiﬁc
vidence  (i.e. from very high to very low), among which was
he  GRADE (Grades of Recommendation Assessment, Develop-
ent  and Evaluation) system, adopted by WHO  in 2007. GRADE
as  initially proposed in Canada for new recommendations
or TB control and became the most widely used system of
valuation  in the last decade in developed countries.15–17 This
ystem  consists of two main parts. The ﬁrst is the degree to
hich  scientiﬁc evidence is derived from studies of models
hat  are more  able to prevent the occurrence of systematic
rrors or bias: clinical trials and systematic reviews of clinical
rials  are the best evidence; observational studies (cohort and
ase–control)  and then, ﬁnally, studies without a comparison
roup  (case studies) and expert opinions are of lesser value
n  this hierarchy. The second part is dictated by the strength
f  the recommendation compiled from studies that should be
sed in changes of clinical guidelines and standards manuals.
owever,  in most instances usually when the GRADE system
s  adopted, only high-quality studies have been used.
Although recommendations regarding the use of diag-
ostic  tests share the same fundamental logic with recom-
endations for therapeutic interventions, they have unique
haracteristics and challenges, brought into sharp focus
hen  applying the GRADE system to the area of testing
nd  diagnostic strategies. In evaluating the results of new
iagnostic  tests/strategies, it has been described that low
ccuracy  greatly limits the clinical value of a test/strategy.
owever, a test with high sensitivity and/or speciﬁcity alone
oes  not guarantee an improvement in outcomes consid-
red  important for doctors and patients. In practice, clinicians
ant  to know how a test/strategy is able to affect clinical3;1  7(2):211–217  213
judgment to be used in decision making about clinical
procedures. What the doctor wants to know is if those
tests/strategies do better in terms of clinical outcomes. Does
the  new diagnostic strategy promote more  appropriate thera-
peutic  interventions? Very rarely is this beneﬁt quite clear in
the literature. Generally, as in the case of tests for early detec-
tion  of asymptomatic disease, this evaluation can only be done
accurately  by tracking individuals who were  randomized to
undergo  the test of interest and another (or no) test.
After two decades of experience, it was observed that the
outcomes  studied from systematic reviews and meta-analyses
in  health of most clinical trials, did not respond to the key
issues  to help deciding whether or not the incorporation of
technology  to the health system is indicated. Additionally,
those studies were  conducted in clinical research centers in
speciﬁc  populations that are not representative of the general
one.  Moreover, these studies have generally not included eval-
uations  of cost effectiveness.18 At the end of the last decade,
a  distinction between explanatory and pragmatic trials began
to  emerge.19 Explanatory clinical trials seek to answer ques-
tions  of efﬁcacy, whether and how an intervention works.
On  the other hand, pragmatic trials are conducted to support
decision-making in health care, and therefore are conducted
in  conditions very close to those provided within the routine
health  services, in patients who are very similar to those who
will  need the treatment in the future. In a recent systematic
review, which included 168,000 randomized controlled trials
conducted  in the period 1976–2002, it was  found that only
95  (0.05%) met  the criteria of pragmatic clinical trials. The
authors  emphasized the urgent need to prioritize the achieve-
ment  of pragmatic trials that may  also answer questions
regarding the applicability of new technology in the health
system  and not just the issues of efﬁcacy used in explanatory
clinical trials, whose main purpose would be to obtain indus-
try  product registration followed by the regulatory agencies
for  their marketing in the private system.20 Additionally, tri-
als  should be designed and reported in such a way  that users
of  the results can make meaningful judgments about appli-
cability  to their own context. As the pragmatic–explanatory
distinction comprises a continuous spectrum, not an either/or
dichotomy  of the extremes, we suggest to follow the innova-
tive  approach proposed by Thorpe et al.12 using the pragmatic
explanatory continuum indicator summary (PRECIS) with the
identiﬁcation  of key domains that distinguish pragmatic from
explanatory  trials.
The  limitation  of  regulatory  approval  for  private
markers and  its  impact  on  innovation  in  the
National Guidelines
In the area of diagnostic tests, the situation is not different.
New  diagnostic tests evaluated with funding from indus-
try  research centers through clinical tests of accuracy have
been  sufﬁcient for approval of registration for marketing by
regulatory  agencies (the United States: Food and Drug Admin-
istration  – FDA;  in Europe Medicine Agency – EMA  and in
Brazil,  the Agência Nacional de Vigilância Sanitária – ANVISA).
These  tests are implemented in the private system as they
become  available, based on experiences with a limited number
i s . 2 0214  b r a z j i n f e c t d 
of cases; i.e. a subjective expectation of its usefulness. As a
result  of lobbying by industries, biomedical companies and
the  media inﬂuenced by marketing in the current economic
system, the logic has been that the individual seeking care in
the  health system must be offered all the technological inno-
vations  produced with some scientiﬁc evidence but without
systematic assessment of their impact on the health system.
By  2007, in the vast majority of countries, with only the uni-
versal  availability of sputum smear microscopy, about 20–30%
of  patients treated in low-income countries were treated for
TB  without bacteriological conﬁrmation. In 2007, in order to
respond  more  effectively to the emergence of co-infection
with TB and HIV and MDR-TB globally, WHO  recommended
new TB diagnostic technologies, such as the use of liquid
culture  for detection of Mycobacterium tuberculosis and DST,
based  on a review of available scientiﬁc evidence and expert
consultation.21–23 In 2008, WHO  recommended the use of
molecular tests for rapid screening of patients suspected of
drug-resistant TB. This recommendation was based on sys-
tematic  reviews, expert opinion and preliminary results of
effectiveness  obtained in demonstration projects (phase III/IV)
clinical  research centers. Such tests should only be used in
respiratory  specimens smear-positive or culture-positive for
mycobacteria.24,25 Pai et al. conducted a systematic review of
studies  evaluating new diagnostic tests for TB, and demon-
strated  the lack of methodological rigor in most studies. The
authors  emphasized that biased results of poorly designed
studies could lead to the adoption of early diagnostic tests that
may  have little or no beneﬁt.26 In recent years, guidelines were
issued  in the standardization of model studies in the area of
infectious  diseases, and to evaluate the accuracy of the new
diagnostic  tests, evaluations of different algorithms (not just
individual  tests, but also their relative contributions to the sys-
tem health care); their incremental value, impact on clinical
practice  over the choices of decision making, studies of cost-
effectiveness under routine conditions, and the impact of new
tools  for the patient and society should all be included.27–29 In
2008,  Wei  et al. analyzed the data published in the literature,
concluding that the new recommendations included in the
national  recommendations or guidelines for TB in developed
countries, used the best scientiﬁc evidence grade (GRADE), and
were  rapidly incorporated into books for review and/or Clini-
cal  Guidelines in middle-income countries with few changes,
without  adjusting them to the local needs of the health of
each  country30 and that most of the clinical guidelines held
in  these countries did not have certiﬁcation by the Appraisal
of  Guidelines for Research & Evaluation (AGREE).31
A recent survey conducted in sixteen high TB burden
countries on the adoption of seven new tools for the diagnosis
of  TB approved by WHO  since 2007, conﬁrmed the deploy-
ment  of new diagnostic tests in TB control policies in half
of  the countries.32 Interestingly, none of the seven countries
carried out an impact assessment (IA) before incorporating
these new technologies, as proposed by WHO  and the STOP
TB  Partnership.33
In the evaluation of new diagnostic tests for drug-
sensitive and drug-resistant TB, tests using liquid culture
(i.e.  Bactec960) or molecular tests (EMTD-GenProbe, Amplicor-
Roche,  Biometrix, MTBDR plus-Life Science) have been rec-
ommended  by the United States FDA and the corresponding 1 3;1 7(2):211–217
body in the European Union (and marketed there). These
molecular tests have been commercialized in the private
sector  in countries with an intermediate level of economic
development (as in Brazil, since 2009). Although there is no
report  in the literature of pragmatic clinical trials and cost-
effectiveness in the use of molecular tests in the diagnostic
approach of drug-resistant TB and TB in developing countries,
the  test Xpert MTB/RIF was recommended by WHO  in Decem-
ber  2010.34
Xpert MTB/RIF is a fully automated molecular testing
device with an integrated processing model designed to purify,
concentrate,  amplify and identify the rpoB target sequences
for  the diagnosis of rifampicin resistance, providing results
in  120 min  from sputum samples without requiring the pres-
ence  of an expert in molecular biology. The results obtained
by  demonstration studies (phase III) conﬁrm the high speci-
ﬁcity  for the diagnosis of TB and drug resistance to rifampicin.
The  72% sensitivity of the test with one sample from sputum
smear-negative patients is similar to that observed with other
molecular  tests such as the Roche Amplicor and the EMTD
GenProbe. Despite the high speciﬁcity (>95%) of Xpert MTB/RIF
for  detection of rifampicin resistance, the test should be used
only  for clinical decision where the prevalence of resistant TB
is  more  than 15%. However, this test can be decentralized to
health  facilities at the secondary level, as it does not require a
molecular biology laboratory for its implementation.35,36
Impact  assessment  framework  as  evidence  for  scale  up
Globally, in recent years, consensus has developed among pol-
icymakers that middle-income countries like Brazil should
lead  processes in the ﬁeld of Health Technology Assessment
and  impact analysis for the incorporation of new technolo-
gies,  focusing on the ability of new technology to improve
or  maintain health. Diagnostic tests should not escape this
principle.
Until  recently, prolonged economic growth and democratic
stability seen in industrialized nations allowed increasing
investment and improvement in the ﬁelds of health and edu-
cation.  Additionally, improving public management allowed
the  anticipation of more  care, better performance, and atten-
tion  to health institutions. In 2004, in Brazil, a Law on
Technological Innovation (Law 10973 of 02/12/2004), regulated
by  Decree No. 5563 of 11.10.2005 was approved. There is visi-
ble  progress in investment in research in Brazil, with growing
space  for initiatives in the ﬁeld of innovation, an area in which
the  country is still behind the progress. The public–private
partnerships, the close interaction of companies with the uni-
versity  arena seems to indicate a welcome progress.
In recent decades, the health biotechnology sector in Brazil
has  made considerable progress toward innovation through
institutes  controlled by the government and the private sector.
However,  despite changes in the national scene in the pub-
lic  institutions of higher education, researchers have worked
in  a very fragmented manner, especially in health, without a
unity of expression and an effective and coordinated strategy
to  address common challenges. With respect to the subject of
publications,  in middle-income countries, the predominance
of  basic research studies in the areas of vaccines, immunology,
b r a z j i n f e c t d i s . 2 0 1 3;1  7(2):211–217  215
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In  general, in middle-income countries, the participation
f  civil society and ﬁnancial support toward investments
n health care, integrating education, research and exten-
ion,  especially in universities, is very welcome. Recently in
razil,  lack of technological innovation and its interface with
ostgraduate programs  were considered as one of the major
hallenges  in the 2012–2020 Plan prepared by Ministry of
ducation.37 On the other hand, within the Ministry of Health
n  2008, the Commission for the Incorporation of Technology
CITEC) of the Ministry of Health, linked to the Department of
cience,  Technology and Strategic Inputs/Ministry of Health
as  created, according to decree No. 2587 of October 30, 2008.38
The incorporation of new, or removal of antiquated equip-
ent/technology, drugs, biological supplies (diagnostic tests)
n  the Uniﬁed Health System (SUS) will occur only when the
ssessment  of such products addresses the following issues:
a)  impact of technology on health, and (b) the technological
elevance established through studies of evaluation of health
echnologies, such as technical-scientiﬁc, systematic reviews,
eta-analysis, economic studies and pragmatic trials.
To  assist in the discussion on this issue, the Interna-
ional Union Against Tuberculosis and Lung Disease and its
egional  partners, including the Brazilian Network of Tuber-
ulosis  Research (REDE-TB) and the Medical School of the
ederal  University of Rio de Janeiro recently published a new
roposal  for a platform to evaluate the impact of new diagnos-
ic  technologies for tuberculosis.39 Using this new platform
f  technology assessment described in Fig. 1, operational
esearch can be prioritized through randomized pragmatic
linical trials, cost analysis and scale-up, and also include
ssues  related to equity, access, qualitative studies with users,
ealth  professionals, managers, and representatives of local
nd  international industries to identify barriers or facilitators
or  the incorporation of new technology in different health
ystems.  Using this platform, it is intended that the discus-
ion  on the merger or dissemination of a new test/strategy for
B  diagnosis can at least answer the simple question: will it
e  better for patients and/or the current health system in the
ountry?
Individual  health values can no longer be the only criterion
n  which decisions are based in industry. It is also necessary todiagnostics, from needs assessment to delivery.
take into account the social cost, the individual acceptance or
time spent by the end-user and/or health care professional. As
mentioned earlier, new diagnostic tools are often immediately
incorporated into the routine of services as soon as they are
approved  for marketing by regulatory agencies, based on their
performance  through the analysis of sensitivity, speciﬁcity or
“receiver operating curves”.
More  recently, Cobelens et al.40 proposed a pathway for
evaluating new tuberculosis diagnostics separating the techni-
cal  and programmatic policy recommendations. This pathway
allows  all stakeholders to distinguish between the statement
about  whether a particular test has sufﬁcient potential to
be  used in tuberculosis control, and the statement about
how,  where, and under which conditions this test should be
implemented.  It acknowledges that these statements require
different  types of evidence that can only be collected in a
phased  manner. Clarity for policy makers, tuberculosis pro-
gram  managers, and donors about this 2-step process will
allow  them to choose between scaling up after technical
policy recommendation(s) only (early adoption by regulatory
agencies as described above) versus waiting until the WHO
has  issued a detailed programmatic policy recommendation.
Countries that adopt a new technology can play an impor-
tant  role in collecting the evidence needed in the stage before
scale-up.
Closing  remarks
The pragmatic approach presented in this manuscript indi-
cates  that it is not appropriate to conduct an investigation
on the incorporation of new technologies only in a “purely
experimental” manner in clinical research centers. Research
and  practice clinical processes become intertwined and the
main  outcomes to be considered are the patient’s health and
actions  creating a more  effective health system in which
the  new technology will be incorporated. In this new sce-
nario,  it is essential that the academic biomedical areas
reformulate their undergraduate curricula to include courses
that  address the development of new technologies, includ-
ing  the assessment of clinical impact, and economic and
social  incorporation of these new technologies into the cur-
rent  health system that will inﬂuence the future practice of
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their graduate students. In parallel, only through collaborative
activities between academics, health service providers (public
or  private), producers of raw materials, laboratories and rep-
resentatives  of civil society will it be possible to conduct such
studies  under routine conditions in demonstration areas to
enable  an analysis appropriate to the relevance of the incor-
poration  of new technologies in the country.
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